Table 1 Summary characteristics of the included studies evaluating frailty in MM therapeutic clinical trials.
|  | N = 43 |
|---|---|
MM disease phase | |
Newly-diagnosed | 26 (60.4%) |
Relapsed/Refractory | 17 (39.5%) |
Study Methodology | |
Randomized controlled clinical trial | 24 (55.8%) |
Non-Randomized controlled clinical trial | 19 (44.2%) |
Clinical Trial Phase | |
Phase I/II | 20 (46.5%) |
Phase III/IV | 18 (41.9%) |
Unknown | 5 (11.6%) |
Multicentre | |
Yes | 38 (88.3%) |
No | 5 (11.6%) |
Geographic Region of Study | |
Europe | 20 (46.5%) |
Global | 11 (25.6%) |
Asia | 7 (16.3%) |
United States | 3 (7.0%) |
Other | 2 (4.6%) |
Reported within last two years (2021, 2022) | 18 (41.9%) |
Reason for Frailty Evaluation* | |
Subgroup analysis | 31 (72.0%) |
Study entry criteria | 8 (18.6%) |
Intervention based upon frailty | 1 (2.3%) |
Drug dosing | 5 (11.6%) |
Longitudinal assessment (> 1 time point) | 4 (9.3%) |
Tools Utilized for Frailty Assessment* | |
International Myeloma Working Group Index | 18 (41.8%) |
Simplified frailty score | 17 (39.5%) |
Other or unknown | 14 (32.6%) |
Frailty Categorization | |
Three (fit-intermediate fit-frail) | 22 (51.2%) |
Two (fit-frail) | 8 (18.6%) |
Continuous | 1 (2.3%) |
Not available or not applicable | 12 (27.9%) |
